About Binnopharm Group
A Top 3 Russian pharmaceutical company in the domestic market*
PHARMACEUTICAL COMPANY
that includes five manufacturing facilities across Russia. The Group produces medicines in various dosage forms (including those from Binnopharm Group’s own active pharmaceutical ingredients), polymer-based medical products, and veterinary medicines.
Binnopharm
Group’s drug portfolio is one of the largest in the Russian pharmaceutical market
and includes generic and original drugs.
450+
marketing
authorisations
authorisations
100+
medicines included in
in the List of Vital and Essential Medicines
200+
pharmacological
groups
groups
Extensive
expertise, cutting-edge technology, diversified and well-balanced product
portfolio, wide footprint, and dynamic growth in the inpatient and retail
segments of domestic and foreign pharmaceutical markets are the Group’s key
competitive advantages.
Binnopharm Group is one of the largest suppliers for the inpatient segment, providing clinics and hospitals with antibiotics in various dosage forms; medicines for endocrinology, neurology, cardiology and other therapeutic groups; and medical devices for blood transfusion.
In the retail segment, Binnopharm Group is represented by renowned branded medicines and INN generics. The Company's products dominate respective sectors in terms of sales volumes.
A team of medical and pharmaceutical representatives help promote our products across all of Russia.
Binnopharm Group’s products are also available in 14 countries.
The Group manufactures up to 500 million units of quality medicines annually
Human
capital development along with constant upgrades of production capacities,
improvement of R&D competencies, and adherence to the world's top quality
control standards is what underpins Binnopharm Group’s operations.
Leadership
Binnopharm
Group's senior executives are a team of professionals with many years of
industry experience who leverage their knowledge and expertise to help the
Company grow and evolve.
Rustem Muratov
Chief Executive Officer, member of the Board of Directors of Binnopharm Group
Dmitry Zubov
Chairman of the Board of Directors of Binnopharm Group,
Chairman of the Board of Centrosoyuz
Chairman of the Board of Centrosoyuz
Vyacheslav
Vorobyev
Vorobyev
Chairman of the Board of Directors of the Kama Group of Companies
Artyom
Zasursky
Zasursky
Vice President for Strategy and Development of Sistema
Oleg
Mubarakshin
Mubarakshin
Managing Partner of Sistema
Rustem
Muratov
Muratov
Chief Executive Officer of Binnopharm Group
Yuri
Kalinin
Kalinin
President of the Russian Union of Associations and Enterprises of the Pharmaceutical and Medical Industry; Chairman of the Commission on the Pharmaceutical and Medical Industry
Stepan
Natalevich
Natalevich
Executive Director of VTB Capital
Alexander
Shevchuk
Shevchuk
Executive Director of the Association of Institutional Investors
Nelly
Naigovzina
Naigovzina
Professor, Head of the Department of Public Health and Healthcare at A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Alexander
Gintsburg
Gintsburg
Director of the Gamaleya Research Institute of Epidemiology and Microbiology, member of the Russian Academy of Sciences, expert in molecular biology and the development of biotech products, including a COVID-19 vaccine
Olga
Ryzhkova
Ryzhkova
Director of the Investment Department of the Russia-China Investment Fund
Our history
Binnopharm
Group began its operations in the Russian market following the merger of
Sistema’s pharmaceutical assets in 2020. Boasting extensive experience and
history, the Company has a number of manufacturing facilities, the largest of
which was built in 1958. The Group’s newest plant came on stream in 2019.
1958
Established as an active pharmaceutical ingredients and antibiotic manufacturer.
1970
First batches of Biomycin produced.
1980
Start of veterinary medicines production.
2000
Product portfolio expanded from 40 medicines to 200. Sintez begins manufacturing new dosage forms: capsules, ointments, drops, etc.
1991
Established as a producer of immunobiological medicines.
2002-2004
Major overhaul of production. Launch of full-cycle manufacturing of solid dosage forms.
2013
Evolution into the only manufacturer in Russia to have an approved vendor status issued by the World Health Organisation.
1994
Founded on the basis of the Research Institute of Applied Microbiology.
2010
Major overhaul of production. Launch of full-cycle manufacturing of solid dosage forms.
2019
Launch of a new production facility. 3x increase in the plant's capacity.
2006
Founded by Sistema as a full-cycle biopharmaceutical company.
2009
Market launch of Regevac B, a hepatitis vaccine. Production of medicines across the key therapeutic groups.
2010
Created as an infusion solutions manufacturer.
2013
Merger of Binnopharm and Alium.
2019
Sistema's acquisition of Sintez and Biocom.
2019
Sistema's acquisition of Obolenskoe.
Merger with Binnopharm.
Merger with Binnopharm.
2020
Launch of Gam-COVID-Vac (Sputnik V) manufacturing.
2020
Sistema
consolidates its pharmaceutical assets under Binnopharm Group.
*according
to AlphaRM
